Sign In
Buy NMRA
$1.74
-0.0100 (-0.571%)
At Close: Jun 03, 2026
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
09:46am, Wednesday, 10'th Jan 2024
Neumora Therapeutics (NMRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 02'nd Jan 2024
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that
7 Stocks with Strong Insider Buying: December 2023
12:35pm, Sunday, 17'th Dec 2023
Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is underv
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
07:00am, Tuesday, 12'th Dec 2023
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
07:00am, Monday, 27'th Nov 2023
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia NMRA-266 is a highly selective positive all
IPO pipeline welcomes some profitable companies, raising hopes for a rebound
01:27pm, Monday, 20'th Nov 2023
The U.S. initial public offering calendar is empty this holiday-shortened week, but some recent additions to the pipeline suggest December could be livelier and welcome deals from some profitable, dec
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
07:00am, Wednesday, 01'st Nov 2023
Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression trial in 1H24
Neumora Therapeutics to Participate in Upcoming Conferences in November
07:00am, Monday, 30'th Oct 2023
WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that
Neumora: First Novel Mechanism Of Action Drug In Major Depression In Decades
07:03pm, Wednesday, 18'th Oct 2023
The lead Neumora Therapeutics, Inc. product candidate, Navacaprent, has shown promise in treating major depressive disorder, MDD, and bipolar depression. The lead product candidate, Navacaprent, is a
Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines Dr. Lenz brings 20 yea
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
07:54pm, Thursday, 28'th Sep 2023
The IPO market in 2023 has been anything but hot. After a record-breaking year in 2021, the appetite for new listings has cooled down significantly, first in 2022 and continuing into the current year.
Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
08:36am, Wednesday, 27'th Sep 2023
Amgen Inc.'s disclosure Wednesday of a large stake in Neumora Therapeutics Inc. indicates that the value of its investment in the biopharmaceutical company, which recently went public, has tripled.
Why Shares of Neumora Therapeutics Slumped This Week
06:06pm, Thursday, 21'st Sep 2023
Neumora focuses on central nervous system disorders. Its lead therapy is Navacaprant to treat MDD.
